Clinical Trial Update: CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1/2 trial of CP-675,206 with neoadjuvant hormone therapy for high-risk prostate cancer. The study status indicates completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CP-675,206

Snippet

Sponsor: AstraZeneca | Conditions: Prostatic Neoplasms | Phase 1, Phase 2 | Status: COMPLETED